Diamyd Medical AB, a biopharmaceutical company, engages in the development of pharmaceuticals for the treatment of autoimmune diabetes and pain. Its diabetes products include the Diamyd drug candidate, which is in Phase III trials in Europe and the United States for the treatment and prevention of autoimmune diabetes. The companyâ€™s products for the treatment of pain consist of three drug candidates in clinical and preclinical phases that use its patented nerve targeting drug delivery system platform for the administration of drugs directly to the nervous system for the treatment of pain. Its products pipeline includes Diamyd for type 1, which is in Phase III clinical trial; Diamyd for LADA, a Phase II clinical trial product; Diamyd for prevention, a Phase II clinical trial product; NP2 Enkephalin, a Phase I clinical trial product for the treatment of cancer pain; NG2 GAD, which is in preclinical stage for the treatment of diabetes pain; and NE2 Endomorphin, which is in preclinical stage for the treatment of chronic pain. The company was founded in 1994 and is headquartered in Stockholm, Sweden.